期刊文献+

甲苯达唑在不同介质中的溶解度研究 被引量:1

Study on the solubility of mebendazole in different solvents
原文传递
导出
摘要 目的研究甲苯达唑在几种油相和水相介质中的溶解度,通过观察溶解度的变化情况,为药物生物利用度的提高奠定基础。方法将甲苯达唑分散于大豆油、甘油三油酸酯以及油酸等9种油相介质中,并以1%西黄耆胶和去离子水作为对照,于25℃或37cC的恒温水浴中以100r/min的速度机械振荡24h后离心,取上清液采用高效液相色谱法(HPLC)测定甲苯达唑在上述介质中的浓度。结果在25℃时甲苯达唑在大豆油、甘油三油酸酯以及油酸中的溶解度分别为(2.1±0.2)μg/ml、(54.1±1.9)μg/ml以及(329.4±9.7)μg/ml,均高于在去离子水(1.0±0.1)μg/ml和1%西黄芪胶(5.5±0.7)μg/ml的溶解度。当介质温度升高到37℃,甲苯达唑在上述溶剂中的溶解度均随着介质温度的升高而增加,其中在3种油相中的溶解度为(34.1±1.9)~(900.7±57.1)μg/ml,而在1%西黄耆胶和去离子水中增加到(7.2±0.7)μg/m1和(3.7±1.2)μg/ml。结论与传统的水相给药介质相比,将甲苯达唑分散于油相溶剂中,可显著增加其溶解度。 Objective To study the solubility of mebendazole in several solvents. Methods Mebendazole was suspended in 9 kinds of oil, such as soybean oil, glycerol trioleate, oleic acid and so on, and in 1% tragacanth and deionized water as control. Then after being kept at 25 ℃ and 37 ℃ water bath for 24 h by 100 r/min, the saturated solution was centrifuged and then assayed by high performance liquid chromatograph (HPLC) to estimate the solubility of mebendazole in each solvent. Results The solubility of mebendazole in soybean oil, glycerol trioleate, oleic acid was (2.1 ± 0.2) μg/ml, (54.1 ± 1.9) μg/ml and (329.4 ± 9.7 ) μg/ml respectively, significantly higher than that in 1% tragacanth [ (5.5 ± 0.7 ) μg/ml) and deionized water ( 1.0 ±0.1 ) μg/ml]. And as the temperature raised to 37 ℃, the solubility of mebendaozle in those solvents was all improved, which was from (34.1± 1.9) - (900.7 ± 57.1 ) ±g/ml in three oil solvents mentioned above and was (7.2 ± 0.7) ±g/ml and (3.7 ±1.2) ±g/ml in 1% tragacanth and deionized water. Conclusion The study showed that the solubility of mebendazole could be increased by suspending in oils comparing with the classic aqueous solutions, and provided the way to promote drug absorption and achieve the ultimate purpose of improving curative effect.
出处 《国际医学寄生虫病杂志》 CAS 2012年第5期292-295,共4页 International JOurnal of Medical Parasitic Diseases
关键词 棘球蚴病 甲苯达唑 溶解度 酸碱度 酸度值 Echinococcosis Mebendazole Solubility pH Acid value
  • 相关文献

参考文献14

  • 1Moro P, Sehantz PM. Echinocoecosis: a review [ J ]. Int J Infect Dis, 2009, 13(2) : 125-133.
  • 2Eckert J, Conraths FJ, Tackmann K. Echinococcosis : an emerging or re-emerging zoonosis [ J ] ? Int J Parasitol, 2000, 30 ( 12-13 ) : 1283-1294.
  • 3Eckert J, Gemmell MA, Meslin FX, et al. WHO/OIE manual on echinococcosis in humans and animals: a public health problem of global concern [ M ]. Paris : Office International des Epizooties, 2001 : 21-72.
  • 4刘丛珊,张皓冰.甲苯达唑治疗棘球蚴病的疗效、代谢及生物利用度的研究进展[J].中国寄生虫学与寄生虫病杂志,2009,27(6):513-519. 被引量:4
  • 5Davis A, Dixon H, Pawlowski ZS. Muhicentre clinical trials of benzimidazole-carbamates in human cystic echinococcosis (phase 2) [J]. Bull World Health Organ, 1989, 67(5) : 503-508.
  • 6Davis A, Pawlowski ZS, Dixon H. Muhicentre clinical trials of benzimidazolecarbamates in human echinococcosis[J]. Bull World Health Organ, 1986, 64(3) : 383-388.
  • 7Keystone JS, Murdoch JK. Mebendazole [ J ]. Ann Intern Med, 1979, 91(4) : 582-586.
  • 8Schantz PM, Van den Bossehe H, Eckert J. Chemotherapy for larval echinococcosis in animals and humans: report of a workshop [J]. Z Parasitenkd, 1982, 67(1): 5-26.
  • 9Daniel-Mwambete K, Torrado S, Cuesta-Bandera C, et al. The effect of solubilization on the oral bioavailability of three benzimidazole carbamate drugs [ J ]. Int J Pharm, 2004, 272 ( 1-2 ) : 29-36.
  • 10Evrard B, Chiap P, DeTullio P, et al. Oral bioavailability in sheep of albendazole from a suspension and from a solution containing hydroxypropyl-beta-cyelodextrin [ J ]. J Control Release, 2002, 85(1-3) : 45-50.

二级参考文献50

  • 1何颖娜,尚京川,张晓萍,母昭德,景淑华,封家富.高效液相色谱法测定人血浆中甲苯咪唑含量[J].第三军医大学学报,2005,27(20):2086-2087. 被引量:8
  • 2杨元清,张超威,肖树华,尤纪青,吴嘉彤,柴君杰,张文林.吡喹酮、甲苯达唑及阿苯达唑对细粒棘球蚴作用的组织化学比较[J].地方病通报,1990,5(3):21-25. 被引量:5
  • 3肖树华,尤纪青,焦佩英,郭惠芳,黄立信,柴君杰,焦伟.甲苯达唑、阿苯达唑及其代谢物实验治疗小鼠继发性细粒棘球蚴病的研究[J].地方病通报,1990,5(3):11-16. 被引量:14
  • 4Schantz PM, Van den Bossche H, Eckert J. Chemotherapy for larval echinococcosis in animals and humans: report of a workshop [J]. Z Parasitenkd, 1982, 67(1): 5-26.
  • 5Munst GJ, Karlaganis G, Bircher J. Plasma concentrations of mebendazole during treatment of echinococcosis: preliminary results [J]. Eur J Clin Pharmacol, 1980, 17(5): 375-378.
  • 6Keystone JS, Murdoch JK. Mebendazole[J]. Ann Int Med, 1979, 91(4): 582-586.
  • 7Morris DL, Dykes PW, Dickson B, et al. Albendazole in hydarid disease[J]. Br Med J (Clin Res Ed), 1983, 286(6359): 103-104.
  • 8Dawson M, Braithwaite PA, Roberts MS, et al. The pharmacokinetics and bioavailability of a tracer dose of [^3H]-mebendazole in man[J]. Br J Clin Pharmacol, 1985, 19(1): 79-86.
  • 9Davis A, Pawlowski S, Dixon H. Muhicentre clinical trials of benzimidazole carbamates in human echinococcosis[J]. Bull WHO, 1986, 64(3): 383-388.
  • 10Davis A, Pawlowski S, Dixon H. Multicentre clinical trials of benzimidazole carbalnates in human echinococcosis (phase 2) [J]. Bull WHO, 1989, 67(5): 503-508.

共引文献3

同被引文献10

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部